An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
Status
Terminated
Conditions
Rheumatoid Arthritis
Details and patient eligibility
About
This observational study will assess the efficacy and safety of MabThera/Rituxan (Rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-TNF therapy. Data will be collected from patients initiated on MabThera/Rituxan therapy according to standard of care in routine clinical practice. For each patient data will be collected for 92 weeks.
Enrollment
1,240 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Adult patients, >/= 18 years of age
- Active Rheumatoid Arthritis
- Inadequate response to anti-TNF
- Eligible for MabThera/Rituxan therapy according to physician's decision
Exclusion criteria
- According to Summary of Product Characteristics
Trial design
1,240 participants in 1 patient group
Cohort
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems